Synopsis
Synopsis
0
VMF
0
Data Compilation #PharmaFlow
0
Stock Recap #PipelineProspector
0
Weekly News Recap #Phispers


1. 1,2 Diaminocyclohexane Platinum Oxalate
2. 1,2-diaminocyclohexane Platinum Oxalate
3. 1,2-diamminocyclohexane(trans-1)oxolatoplatinum(ii)
4. Act 078
5. Act-078
6. Act078
7. Cis-oxalato-(trans-l)-1,2-diaminocyclohexane-platinum(ii)
8. Eloxatin
9. L-ohp Cpd
10. Oxalato-(1,2-cyclohexanediamine)platinum Ii
11. Oxaliplatin
12. Oxaliplatin, (sp-4-2-(1r-trans))-isomer
13. Oxaliplatin, (sp-4-2-(1s-trans))-isomer
14. Oxaliplatin, (sp-4-3-(cis))-isomer
15. Oxaliplatine
16. Platinum(2+) Ethanedioate (1r,2r)-1,2-cyclohexanediamine (1:1:1)
17. Platinum(ii)-1,2-cyclohexanediamine Oxalate
1. (1r,2r)-cyclohexane-1,2-diamine;oxalic Acid;platinum
2. Foloxatine
3. L-platin
4. Oxaliplatin,(s)
5. Oxaliplatin, Solid
6. Gsox
7. Mls000028569
8. Act-078
9. Hms2089p18
10. Akos015964329
11. Akos016016346
12. Ac-2110
13. Gs-3610
14. 111ge010
15. Smr000058995
16. Ab00698415-04
17. Ab00698415-05
18. 825o943
19. Brd-m14820059-001-04-0
20. Oxaliplatin, European Pharmacopoeia (ep) Reference Standard
21. Platinum(2+) Ion (1r,2r)-cyclohexane-1,2-diamine Oxalate
22. Oxaliplatin, United States Pharmacopeia (usp) Reference Standard
23. Oxaliplatin, Pharmaceutical Secondary Standard; Certified Reference Material
| Molecular Weight | 399.31 g/mol |
|---|---|
| Molecular Formula | C8H16N2O4Pt |
| Hydrogen Bond Donor Count | 4 |
| Hydrogen Bond Acceptor Count | 6 |
| Rotatable Bond Count | 0 |
| Exact Mass | 399.075801 g/mol |
| Monoisotopic Mass | 399.075801 g/mol |
| Topological Polar Surface Area | 127 Ų |
| Heavy Atom Count | 15 |
| Formal Charge | 0 |
| Complexity | 139 |
| Isotope Atom Count | 0 |
| Defined Atom Stereocenter Count | 2 |
| Undefined Atom Stereocenter Count | 0 |
| Defined Bond Stereocenter Count | 0 |
| Undefined Bond Stereocenter Count | 0 |
| Covalently Bonded Unit Count | 3 |
Antineoplastic Agents
Substances that inhibit or prevent the proliferation of NEOPLASMS. (See all compounds classified as Antineoplastic Agents.)

API/FDF Prices: Book a Demo to explore the features and consider upgrading later
API Imports and Exports
| Importing Country | Total Quantity (KGS) |
Average Price (USD/KGS) |
Number of Transactions |
|---|
Upgrade, download data, analyse, strategize, subscribe with us
DRUG PRODUCT COMPOSITIONS
Related Excipient Companies
Excipients by Applications
Global Sales Information
Market Place
Patents & EXCLUSIVITIES
REF. STANDARDS & IMPURITIES
ABOUT THIS PAGE
39
PharmaCompass offers a list of Oxaliplatin API manufacturers, exporters & distributors, which can be sorted by GMP, USDMF, JDMF, KDMF, CEP (COS), WC, Price,and more, enabling you to easily find the right Oxaliplatin manufacturer or Oxaliplatin supplier for your needs.
Send us enquiries for free, and we will assist you in establishing a direct connection with your preferred Oxaliplatin manufacturer or Oxaliplatin supplier.
PharmaCompass also assists you with knowing the Oxaliplatin API Price utilized in the formulation of products. Oxaliplatin API Price is not always fixed or binding as the Oxaliplatin Price is obtained through a variety of data sources. The Oxaliplatin Price can also vary due to multiple factors, including market conditions, regulatory modifications, or negotiated pricing deals.
A Eloxatin manufacturer is defined as any person or entity involved in the manufacture, preparation, processing, compounding or propagation of Eloxatin, including repackagers and relabelers. The FDA regulates Eloxatin manufacturers to ensure that their products comply with relevant laws and regulations and are safe and effective to use. Eloxatin API Manufacturers are required to adhere to Good Manufacturing Practices (GMP) to ensure that their products are consistently manufactured to meet established quality criteria.
click here to find a list of Eloxatin manufacturers with USDMF, JDMF, KDMF, CEP, GMP, COA and API Price related information on PhamaCompass.
A Eloxatin supplier is an individual or a company that provides Eloxatin active pharmaceutical ingredient (API) or Eloxatin finished formulations upon request. The Eloxatin suppliers may include Eloxatin API manufacturers, exporters, distributors and traders.
click here to find a list of Eloxatin suppliers with USDMF, JDMF, KDMF, CEP, GMP, COA and API Price related information on PharmaCompass.
A Eloxatin DMF (Drug Master File) is a document detailing the whole manufacturing process of Eloxatin active pharmaceutical ingredient (API) in detail. Different forms of Eloxatin DMFs exist exist since differing nations have different regulations, such as Eloxatin USDMF, ASMF (EDMF), JDMF, CDMF, etc.
A Eloxatin DMF submitted to regulatory agencies in the US is known as a USDMF. Eloxatin USDMF includes data on Eloxatin's chemical properties, information on the facilities and procedures used, and details about packaging and storage. The Eloxatin USDMF is kept confidential to protect the manufacturer’s intellectual property.
click here to find a list of Eloxatin suppliers with USDMF on PharmaCompass.
The Pharmaceuticals and Medical Devices Agency (PMDA) established the Japan Drug Master File (JDMF), also known as the Master File (MF), to permit Japanese and foreign manufacturers of drug substances, intermediates, excipients, raw materials, and packaging materials (‘Products’) to voluntarily register confidential information about the production and management of their products in Japan.
The Eloxatin Drug Master File in Japan (Eloxatin JDMF) empowers Eloxatin API manufacturers to present comprehensive information (e.g., production methods, data, etc.) to the review authority, i.e., PMDA (Pharmaceuticals & Medical Devices Agency).
PMDA reviews the Eloxatin JDMF during the approval evaluation for pharmaceutical products. At the time of Eloxatin JDMF registration, PMDA checks if the format is accurate, if the necessary items have been included (application), and if data has been attached.
click here to find a list of Eloxatin suppliers with JDMF on PharmaCompass.
In Korea, the Ministry of Food and Drug Safety (MFDS) is in charge of regulating pharmaceutical products and services.
Pharmaceutical companies submit a Eloxatin Drug Master File in Korea (Eloxatin KDMF) to the MFDS, which includes comprehensive information about the production, processing, facilities, materials, packaging, and testing of Eloxatin. The MFDS reviews the Eloxatin KDMF as part of the drug registration process and uses the information provided in the Eloxatin KDMF to evaluate the safety and efficacy of the drug.
After submitting a Eloxatin KDMF to the MFDS, the registered manufacturer can provide importers or distributors with the registration number without revealing confidential information to Korean business partners. Applicants seeking to register their Eloxatin API can apply through the Korea Drug Master File (KDMF).
click here to find a list of Eloxatin suppliers with KDMF on PharmaCompass.
A Eloxatin CEP of the European Pharmacopoeia monograph is often referred to as a Eloxatin Certificate of Suitability (COS). The purpose of a Eloxatin CEP is to show that the European Pharmacopoeia monograph adequately controls the purity of Eloxatin EP produced by a given manufacturer. Suppliers of raw materials can prove the suitability of Eloxatin to their clients by showing that a Eloxatin CEP has been issued for it. The manufacturer submits a Eloxatin CEP (COS) as part of the market authorization procedure, and it takes on the role of a Eloxatin CEP holder for the record. Additionally, the data presented in the Eloxatin CEP (COS) is managed confidentially and offers a centralized system acknowledged by numerous nations, exactly like the Eloxatin DMF.
A Eloxatin CEP (COS) is recognised by all 36 nations that make up the European Pharmacopoeia Convention. Eloxatin CEPs may be accepted in nations that are not members of the Ph. Eur. at the discretion of the authorities there.
click here to find a list of Eloxatin suppliers with CEP (COS) on PharmaCompass.
A Eloxatin written confirmation (Eloxatin WC) is an official document issued by a regulatory agency to a Eloxatin manufacturer, verifying that the manufacturing facility of a Eloxatin active pharmaceutical ingredient (API) adheres to the Good Manufacturing Practices (GMP) regulations of the importing country. When exporting Eloxatin APIs or Eloxatin finished pharmaceutical products to another nation, regulatory agencies frequently require a Eloxatin WC (written confirmation) as part of the regulatory process.
click here to find a list of Eloxatin suppliers with Written Confirmation (WC) on PharmaCompass.
National Drug Code is a comprehensive database maintained by the FDA that contains information on all drugs marketed in the US. This directory includes information about finished drug products, unfinished drug products, and compounded drug products, including those containing Eloxatin as an active pharmaceutical ingredient (API).
The FDA updates the NDC directory daily. The NDC numbers for Eloxatin API and other APIs are published in this directory by the FDA.
The NDC unfinished drugs database includes product listing information submitted for all unfinished drugs, such as active pharmaceutical ingredients (APIs), drugs intended for further processing and bulk drug substances for compounding.
Pharmaceutical companies that manufacture Eloxatin as an active pharmaceutical ingredient (API) must furnish the FDA with an updated record of all drugs that they produce, prepare, propagate, compound, or process for commercial distribution in the US at their facilities.
The NDC directory also contains data on finished compounded human drug products that contain Eloxatin and are produced by outsourcing facilities. While these outsourcing facilities are not mandated to assign a Eloxatin NDC to their finished compounded human drug products, they may choose to do so.
click here to find a list of Eloxatin suppliers with NDC on PharmaCompass.
Eloxatin Active pharmaceutical ingredient (API) is produced in GMP-certified manufacturing facility.
GMP stands for Good Manufacturing Practices, which is a system used in the pharmaceutical industry to make sure that goods are regularly produced and monitored in accordance with quality standards. The FDA’s current Good Manufacturing Practices requirements are referred to as cGMP or current GMP which indicates that the company follows the most recent GMP specifications. The World Health Organization (WHO) has its own set of GMP guidelines, called the WHO GMP. Different countries can also set their own guidelines for GMP like China (Chinese GMP) or the EU (EU GMP).
PharmaCompass offers a list of Eloxatin GMP manufacturers, exporters & distributors, which can be sorted by USDMF, JDMF, KDMF, CEP (COS), WC, API price, and more, enabling you to easily find the right Eloxatin GMP manufacturer or Eloxatin GMP API supplier for your needs.
A Eloxatin CoA (Certificate of Analysis) is a formal document that attests to Eloxatin's compliance with Eloxatin specifications and serves as a tool for batch-level quality control.
Eloxatin CoA mostly includes findings from lab analyses of a specific batch. For each Eloxatin CoA document that a company creates, the USFDA specifies specific requirements, such as supplier information, material identification, transportation data, evidence of conformity and signature data.
Eloxatin may be tested according to a variety of international standards, such as European Pharmacopoeia (Eloxatin EP), Eloxatin JP (Japanese Pharmacopeia) and the US Pharmacopoeia (Eloxatin USP).